Pharmacokinetics of Besifovir in Adults With Normal and Impaired Renal Function

Phase 1 Unknown 40 enrolled IlDong Pharmaceutical Co Ltd

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will evaluate the pharmacokinetics (PK), safety, and tolerability of a single oral dose of Besifovir and its metabolite, LB80331, in participants with normal and impaired renal function

Timeline

Start: 2020-02-13
Primary completion: 2020-09
Completion: 2021-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Besifovir	Other / unclassified	150 mg	Oral

Pharmacokinetics of Besifovir in Adults With Normal and Impaired Renal Function

Summary

Timeline

Drugs

Indications